Announced details
Treatment of muscular dystrophies, including myotonic dystrophy type 1 (DM1), and regulation of DMPK gene expression
The company received a notice of allowance for the U.S. patent application it filed.
U.S. patent examination authority. Other information, including its location, representative, capital and year established, is Not disclosed.
U.S. patent application number 17/614,461. The patent grant date, patent number and expiry date are Not disclosed.
The company believes this is significant in protecting the future business value of MDL-202. The specific impact on financial results is Not disclosed.
The company does not address Contract Value / Offering price.
U.S. Patent and Trademark Office (USPTO)
| Item | Details |
|---|---|
| Names of Products / Services Covered | MDL-202, CRISPR-GNDM® |
| Counterparty | U.S. Patent and Trademark Office (USPTO) |
| Counterparty overview | U.S. patent examination authority. Other information, including its location, representative, capital and year established, is Not disclosed. |
| Relationship with the Company | The company received a notice of allowance for the U.S. patent application it filed. |
| Applicable area | Treatment of muscular dystrophies, including myotonic dystrophy type 1 (DM1), and regulation of DMPK gene expression |
| Registration number and expiry date | U.S. patent application number 17/614,461. The patent grant date, patent number and expiry date are Not disclosed. |
| Impact on Business Performance | The company believes this is significant in protecting the future business value of MDL-202. The specific impact on financial results is Not disclosed. |
| Source | U.S. Patent and Trademark Office (USPTO) |
Items this document does not state (10)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.To strengthen the intellectual property foundation for the DM1 treatment approach using CRISPR-GNDM® and protect the future business value of MDL-202.